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Abstract 
The electrochemical oxidation mechanism of the anti-cancer drug and kinases inhibitor 
danusertib was studied by cyclic, differential pulse, square wave voltammetry and a glassy 
carbon electrode. Danusertib undergoes oxidation in a cascade mechanism and depending on 
the pH of the supporting electrolyte several oxidation peaks were observed. The number of 
electrons and protons involved in each oxidation step as well as the pKa ~ 10.0 were 
determined. The analytical determination of danusertib was carried out in pH = 7.0 by square 
wave voltammetry with LOD = 27.4 nM and UV-VIS spectrophotometry with LOD = 0.5 
µM. Different electroactive centres of danusertib were identified through comparative studies 
with similar compounds such as imatinib and piperazine, and an oxidation mechanism of 
danusertib proposed.  
 
Keywords: danusertib; kinase inhibitor; glassy carbon; redox mechanism; analytical 
determination. 
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1 Introduction 
Protein kinases represent a major class of enzymes that play an important role in 
signal transduction pathways, regulating a number of cellular functions such as cell growth, 
differentiation and cell death [1,2]. Aurora kinases are serine/threonine kinases essential for 
mitosis, cytokinesis and deregulated chromosome segregation [3] and are overexpressed in 
many malignancies, including pancreatic, colorectal, ovarian, and oesophageal cancer [4].  
In view of the critical role that kinases play in cellular environment, and their 
overexpression in tumour cells, enzyme kinases were considered excellent targets for 
anticancer therapy [5]. Several kinase inhibitors were developed and their potential against 
various cancers have been described during different phases of treatment [6,7].  
Danusertib (formally PHA-739358) [8,9], Scheme 1A, is a new, small ATP 
competitive molecule that inhibits Aurora kinases in vitro and in vivo [10]. Also, danusertib 
binds and inhibits with high affinity (IC50 < 0.50 µM) several other tyrosine kinases such as 
Abl, Ret, FGFR-1 and TrkA which are involved in the pathogenesis of a variety of cancers 
[11]. The cross-reactivity of danusertib with different receptor kinases has great anticancer 
therapeutic potential [12], turning this drug effective for the treatment of multiple tumour 
models [4]. 
Clinical trials for the determination of danusertib efficacy in treatment of prostate 
[13], gastroenteropancreatic [14], hepatic [15], and haematological [16] malignancies have 
shown a favourable pharmacokinetic and safety profile. Despite the positive results, resistance 
to danusertib treatment emerged during several studies, but its ability in producing molecular 
complete remissions of tumours was improved using combinations with traditional anti-
neoplastic agents [17].  
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Being a relatively new drug, most references in the specialized literature deal with 
clinical studies. The crystal structure of the Abl kinase mutant in complex with danusertib has 
been resolved and the mechanism by which danusertib may be used to treat resistant 
leukaemia cells explained [18]. However, considering the importance of danusertib as a 
chemotherapeutic agent, suitable analytical procedures are required so that issues such as 
drug-drug or drug-biomolecular complex interactions can be evaluated.  
Electroanalytical methods are fast, inexpensive, and the investigation of the 
electrochemical oxidation mechanisms of compounds has the potential for providing valuable 
insights into their biological redox reactions. Electroanalysis has been successfully used to 
determine the redox mechanism of several pharmaceutical compounds and to quantitate 
different types of drugs [19-24].  
In this context, the aim of the present study is the investigation of the electron transfer 
properties of danusertib using a glassy carbon electrode and electrochemical techniques, 
cyclic, differential pulse and square wave voltammetry. In order to understand and explain 
danusertib redox reactions, its electrochemical behaviour was compared with chemical 
analogues such as imatinib mesyla e, Scheme 1B, and piperazine citrate. The analytical 
determination of danusertib had been also carried by voltammetry and UV-VIS 
spectrophotometry.  
 
2 Experimental 
2.1 Materials and reagents 
Danusertib from Selleck Chemicals, imatinib mesylate from Novartis (Portugal) and 
piperazine citrate from Merck were used without purification. All supporting electrolyte 
solutions, Table 1, were prepared using analytical grade reagents and purified water from a 
Millipore Milli-Q system (conductivity ≤ 0.1 μS cm-1). Stock solutions of 5 mM danusertib 
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and 1 mM imatinib mesylate in ethanol and 1 mM piperazine citrate in deionised water were 
kept at +4 °C until further utilisation. Solutions of different concentrations of danusertib, 
imatinib mesylate and piperazine citrate were obtained by dilution of the appropriate volume 
in supporting electrolyte.  
Microvolumes were measured using EP-10 and EP-100 Plus Motorized Microliter 
Pippettes (Rainin Instrument Co. Inc., Woburn, USA). The pH measurements were carried 
out with a Crison micropH 2001 pH-meter with an Ingold combined glass electrode. All 
experiments were done at room temperature (25±1°C). 
 
2.2 Voltammetric parameters and electrochemical cells 
Voltammetric experiments were carried out using a CompactStat.e running with 
IviumSoft 2.124, Ivium Technologies, The Netherlands. The measurements were carried out 
using a three-electrode system in a 0.5 mL one-compartment electrochemical cell. A glassy 
carbon (GCE, d = 1.0 mm), a Pt wire, and a Ag/AgCl (3 M KCl) were used as working, 
auxiliary and reference electrodes, respectively.  
The experimental conditions for differential pulse voltammetry (DPV) were: pulse 
amplitude of 50 mV, pulse width of 100 ms and scan rate of 5 mV s-1. For square wave 
voltammetry (SWV) a pot ntial increment of 2 mV and pulse amplitude of 50 mV were 
always used. The frequency and consequently the effective scan rate are indicated in the text.  
The GCE was polished using diamond spray, particle size 3 μm (Kemet, UK) before 
each electrochemical experiment. After polishing, it was rinsed thoroughly with Milli-Q 
water. Following this mechanical treatment, the GCE was placed in buffer supporting 
electrolyte and differential pulse voltammograms were recorded until a steady state baseline 
voltammogram was obtained. This procedure ensured very reproducible experimental results. 
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2.3 UV-VIS spectrophotometry 
Absorption spectra were recorded using a UV-VIS spectrophotometer SPECORD 
S100 from Carl Zeiss Technology with Win-Aspect software and a 10 mm quartz cuvette. 
The experimental conditions for absorption spectra were: integration time 25 ms and 
accumulation 1000 points. All UV-VIS spectra were measured from 200 nm to 400 nm. 
 
2.4 Acquisition and presentation of data 
All differential pulse and square wave voltammograms presented were smoothed and 
baseline-corrected using an automatic function included in the IviumSoft version 2.124. This 
mathematical treatment improves the visualization and identification of peaks over the 
baseline without introducing any artefact, although the peak current is in some cases reduced 
(< 10%) relative to that of the untreated curve. Nevertheless, this mathematical treatment of 
the original voltammograms was used in the presentation of all experimental voltammograms 
for a better and clearer identification of the peaks. The values for peak current presented in all 
graphs were determined from the original untreated voltammograms. 
Origin Pro 8.0 from OriginLab Corporation was used for the presentation of all the 
experimental data reported in this work. 
 
3 Results and discussion 
3.1 Cyclic voltammetry 
The voltammetric behaviour of danusertib at a clean GCE was initially investigated in 
the potential range +1.40 V until -1.20 V, by cyclic voltammetry (CV) in 0.1 M phosphate 
buffer pH = 7.0, in a N2-saturated solution (not shown). Peaks were observed in the anodic 
region showing that danusertib undergoes oxidation at the GCE surface. For this reason, all 
subsequent experiments were carried out in the anodic region.  
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The oxidation of danusertib was investigated by CV in solutions of 50 µM danusertib 
in 0.1 M supporting electrolytes with 2.0 < pH < 12.0.  
Cyclic voltammograms recorded in a solution of 50 µM danusertib in pH = 3.4 
showed three consecutive anodic charge transfer reactions: peak 1a at Ep1a = +0.97 V, peak 2a 
at Ep2a = +1.03 V and a small peak 3a at Ep3a = +1.22 V, Fig. 1A. Reversing the scan direction, 
a cathodic peak appeared at Epc = +0.85 V. By recording successive voltammograms in the 
same solution without cleaning the GCE surface, the decrease of all peaks was due to the 
adsorption of danusertib oxidation products at the GCE surface, reducing the electroactive 
area. No additional signal was observed showing that the oxidation products of danusertib are 
not electroactive.  
In order to clarify the origin of the cathodic peak at +0.85 V, two new experiments 
were carried out in the same solution always with a clean GCE surface. In the first 
experiment, the scan direction was inverted at +0.96 V, which corresponded to peak 1a but 
before occurrence of peak 2a. No cathodic reaction was observed in these conditions, Fig. 1A. 
In a new experiment, changing the scan direction at +1.15V, i.e. after the occurrence of peak 
2a but before 3a, the cathodic correspondent peak 2c appeared at Ep2c = +0.85 V, Fig. 1A.  
Also, cyclic voltammograms were recorded in a solution of 50 µM danusertib in pH = 
5.7, and peaks 1a, 2a and 3a were observed, Fig. 1B. The potential difference between peaks 1a 
and 2a decreased relative to the voltammogram recorded in solutions with lower pH values, 
Fig. 1A, hence peaks 1a and 2a overlapped. However, after changing the scan direction, the 
cathodic correspondent peak 2c appeared. Successive cyclic voltammograms were recorded 
without cleaning the electrode surface and peak currents decreased.  
The effect of scan rate on the oxidation of danusertib was evaluated in pH = 7.0 (not 
shown). In these conditions, peaks 1a and 2a merged and only one anodic peak was observed. 
Increasing the scan rate the peak potential shifted to more positive values. The peak current 
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increased but the linear relationship log Ipa vs. log v with a slope of -0.75 showed that the 
oxidation of danusertib involves adsorption of the compound at the GCE surface. Also, an 
increase of the ratio between the anodic and the cathodic peak currents was observed. 
Cyclic voltammograms recorded in solutions of danusertib in supporting electrolytes 
with different pH values showed that danusertib oxidation is pH-dependent. 
 
3.2 Differential pulse voltammetry 
The pH effect on the electrochemical oxidation of danusertib was investigated for 
electrolytes with 2.0 < pH < 12.0, using different voltammetric techniques. DPV allowed 
lower detection limits and a better visualisation of all redox processes. DP voltammograms 
were recorded in solutions of 5 µM danusertib in electrolytes with different pH values, Fig. 
2A. 
For pH < 5.0, three charge transfer reactions at peak 1a, 2a and 3a were observed, Fig. 
2A. The peak potentials were pH dependent and shifted linearly to less positive values with 
increasing pH, Fig. 2B. For peak 1a, the relationship was Ep1a = 0.97 - 0.03 pH. The slope of 
the line, -30 mV per pH unit, corresponded to a mechanism in which the number of protons 
transfer is half of the number of electrons. For peaks 2a and 3a, the relationships were Ep2a = 
1.12 – 0.06 pH and Ep3a = 1.48 – 0.06 pH, respectively. The slopes of -60 mV per pH unit 
were in agreement with oxidation reactions that involved the transfer of the same number of 
electrons and protons. 
For electrolytes with 5.7 < pH < 9.2, only one, pH-dependent peak was observed, Fig. 
2A. The width at half height of the peak (W1/2) varied between 75 and 80 mV, which is higher 
than the theoretical value for a system that involves the transfer of 2 electrons but smaller than 
the value correspondent to 1 electron. The value of W1/2 can be explained considering the 
overlapping of peaks 1a and 2a, Fig. 2B, each corresponding to the transfer of two electrons. 
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For pH > 10.0, peak 1a appeared at higher potential values than peak 2a, Fig. 2A. In 
these conditions, the potential of peak 1a was pH-independent, Fig. 2B, suggesting an 
oxidation mechanism that involves only the transfer of electrons after chemical deprotonation. 
The value of pKa ~ 10.0 of danusertib was determined.  
Consecutive DP voltammograms were recorded in solutions of different 
concentrations and pH values, and after the transfer of the electrode to the supporting 
electrolyte, Fig. 3.  
For pH = 4.5, the voltammogram recorded in 1 µM danusertib showed both peaks 1a 
and 2a, Fig. 3A. By recording successive voltammograms, no additional signal occurred 
showing that the oxidation products of danusertib are not electroactive. After recording two 
voltammograms in solution, the electrode was washed with a jet of deionised water and 
placed in the electrochemical cell containing only buffer. The first voltammogram showed 
both peaks 1a and 2a, Fig. 3A. On the second voltammogram recorded in the same conditions, 
without cleaning the electrode surface, only a small peak 2a occurred, Fig. 3A.  
A similar experiment has been carried out at pH = 5.7, Fig. 3B. On the first DP 
voltammogram recorded in 0.1 µM danusertib peaks 1a and 2a overlapped, hence one peak 
occurred. On the second scan in solution without cleaning the GCE surface a better 
visualisation of both peaks 1a and 2a was observed and their currents decreased. 
 
3.3 Square wave voltammetry 
In SWV the current is sampled in both positive and negative-going pulses, oxidation 
and reduction peaks of the electroactive compound can be obtained simultaneously, and the 
reversibility of the electron transfer reaction monitored by plotting the forward and backward 
components of the total current. 
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SW voltammograms were recorded in solutions of 5 µM danusertib in electrolytes 
with different pH values, Fig. 4. 
At pH = 2.0, three peaks 1a, 2a and 3a were observed, Fig. 4A. The forward and 
backward components of the total current showed peaks corresponding to oxidation at peaks 
1a and 3a, and to oxidation and reduction at peak 2a. This experiment confirmed that 
danusertib oxidation at peaks 1a and 3a is irreversible whereas the redox reaction at peak 2a is 
reversible.  
At pH =12.0, only peaks 2a and 1a occurred, Fig. 4B. The deconvolution of the total 
current showed at peak 2a unequal values for both current and potential. This can be explained 
considering that danusertib oxidation at peak 2a involve the formation of a product that 
undergoes homogenous chemical reaction. At the same time, the irreversibility of danusertib 
oxidation at peak 1a was observed one more time.  
 
3.4 Analytical determination 
The analytical determination of danusertib was investigated by SWV and UV-VIS 
spectrophotometry, Fig. 5 and Table 2.  
SW voltammograms were recorded for standard additions of danusertib corresponding 
to bulk concentrations between 50 and 500 nM in pH = 7.0, Fig. 5A. The detection limit 
(LOD) was determined as the substance concentration that led to a peak with a height three 
times the baseline noise level, and was calculated from LOD = 3 × S.D. × (sensitivity)−1. 
Using the equation Ipa = Ipa(Cdanusertib), the obtained LOD = 27.4 nM, Table 2. The 
quantification limit (LOQ) is the lowest concentration of a substance that can be quantified 
with acceptable precision and accuracy. A typical signal/noise ratio of 10 is generally 
considered to be acceptable; therefore: LOQ = 10 × S.D. × (sensitivity)−1. Thus, LOQ = 91.2 
nM was determined.  
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UV-VIS spectra were recorded for standard additions of danusertib corresponding to 
bulk concentrations between 1 and 10 µM in pH = 7.0, Fig. 5B. Danusertib has shown three 
absorption bands: at 204, 217 and 301 nm. The well-defined absorption band at 301 nm was 
used as analytical signal for the determination of the calibration curve. Using the equations A 
= A(Cdanusertib), LOD = 0.5 µM and LOQ = 1.6 µM were determined.  
The reproducibility of these methods was evaluated by plotting different calibration 
curves. The relative standard deviations (R.S.D.), Table 2, calculated from the sensitivities of 
three calibration curves were around 5.6 % and 0.5 % for SWV and UV-VIS procedures, 
respectively. It must be mentioned that each electrochemical measurement was done using a 
freshly polished GCE, a process that give rise to small modifications of the electrode surface 
area which can in turn cause variations in the oxidation currents, which was the main source 
of error in the electrochemical procedure described. 
 
3.5 Oxidation mechanism 
The electrochemical oxidation of danusertib in acid media showed three consecutive, 
pH-dependent charge transfer reactions at peaks 1a, 2a and 3a, Fig. 6A. The potential of peak 
1a is pH dependent and its value increases with the pH following a linear relationship of -30 
mV / pH unit. Also, peaks 2a and 3a varied with -60 mV / pH unit. The small potential 
difference between peaks 1a and 2a, and their different variations with the pH, allow peaks 1a 
and 2a to overlap in neutral and mild alkaline electrolytes, Fig. 2B. For pH > 10.0, the 
oxidation at peak 1a turns pH independent, and peaks 1a and 2a occur at distinct potential 
values, Fig. 2B. The behaviour described is consistent with the existence of three different 
electroactive centres in the danusertib molecule. 
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For the determination of danusertib oxidation mechanism, experiments have been 
carried out in solutions of imatinib mesylate and piperazine citrate, which present similar 
molecular features with danusertib. 
On the first DP voltammogram in a solution of 5 µM imatinib mesylate in pH = 4.5, 
two consecutive charge transfer reactions were observed at +0.87 V and +1.22 V, Fig. 6B. On 
the second DP voltammogram, the oxidation product of imatinib appeared at +0.32 V. 
Previous results have been shown that the oxidation of imatinib is irreversible and involves 
the formation of an oxidation product that undergoes reversible redox reactions [19,20]. 
The DP voltammogram recorded in a solution of 5 µM piperazine citrate in pH = 4.5 
showed one oxidation peak at +1.23 V, Fig. 6B.  
Comparing the voltammetric behaviour of danusertib and imatinib mesylate, Fig. 6A 
and B, and considering their chemical structures, Schemes 1A and B, an oxidation mechanism 
of danusertib is proposed. For pH < 10.0, the irreversible oxidation of danusertib at peak 1a 
corresponds to the removal of two electrons and one proton from the amide moiety, Scheme 
2A. This oxidation reaction results in a nitrenium (aminylium) cation, in agreement with 
previous reports on the oxidation of amides [27-29]. For pH > 10.0, the amide group 
undergoes chemical deprotonation and the oxidation involves only the transfer of electrons. 
The oxidation of imatinib is similar, but the formation of a quinone structure [19,20] at the 
aromatic ring in the vicinity of the amide group, Scheme 1B, explains the occurrence of the 
oxidation product observed in the solution of imatinib, Fig. 6A. In the case of danusertib, this 
aromatic ring is absent, Scheme 1A, and no electroactive oxidation product was observed, 
Fig. 6A, hence the oxidation product of danusertib undergoes a chemical reaction. It is 
proposed that the nitrenium cation reacts with water in agreement with previous results 
[30,31], resulting in a N-hydroxy amide derivative, Scheme 1A. On the other hand, the small 
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difference (~ 40 mV) between the oxidation peaks of danusertib and imatinib, Fig. 6A and B, 
is due to steric effects imposed by the uncommon moieties in their structures. 
The voltammograms in the solution of danusertib in acid media show the reversible 
charge transfer reaction at peak 2a, Fig. 4A and 6A, which does not not occur in solutions of 
imatinib, Fig. 6B. It is proposed that this reaction is due to the transfer of two electrons and 
two protons from the pyrrolo-pyrazol moiety, Scheme 2B, with the formation of an oxidation 
product that undergoes reaction with water in alkaline electrolytes, Fig. 4B and Scheme 2B.  
For peak 3a of danusertib, Fig. 6A and B, it is proposed that the oxidation involves the 
piperazine moiety. The redox behaviour of piperazine containing compounds has been 
previously reported [22-26]. Considering that in acid media piperazine moiety is protonated 
(pKa1 ~ 7 and pKa2 ~ 3), the electrochemical oxidation of danusertib at peak 3a occurs with the 
transfer of two electrons and two protons from the nitrogen atom in the proximity of the 
methyl group leading to the formation of iminium cation, Scheme 2C, which is hydrolysed 
forming an amine derivative and formaldehyde [26].  
 
4 Conclusion 
The electrochemical oxidation mechanism of the anti-cancer drug and kinase inhibitor 
danusertib has been studied at a glassy carbon electrode by cyclic, differential pulse and 
square wave voltammetry. Three consecutive, pH-dependent charge transfer reactions were 
observed in electrolytes with pH values correspondent to acid media. For neutral and alkaline 
electrolytes one or two oxidation peaks occurred, respectively. The number of electrons and 
protons involved in each step of danusertib oxidation mechanism, and the value of pKa ~ 10.0 
were calculated.  
The analytical determination of danusertib was carried out by square wave 
voltammetry and UV-VIS spectrophotometry at 0.1 M phosphate buffer pH = 7.0. The 
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detection limits were 27.4 nM and 0.5 µM, respectively. The limits of quantification were 
calculated and the reproducibility of the methods was also evaluated.  
The investigation of compounds with similar structures such as imatinib mesylate and 
piperazine citrate allowed the identification of danusertib electroactive centres and a redox 
mechanism of danusertib was proposed. 
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Table 1. Supporting electrolytes, 0.1 M ionic strength. 
 
pH Composition 
2.0 HCl + KCl 
3.4 HAcO+NaAcO 
4.5 HAcO+NaAcO 
5.7 HAcO+NaAcO 
6.0 HAcO+NaAcO 
7.0 NaH2PO4+Na2HPO4 
8.0 NaH2PO4+Na2HPO4 
9.2 NaH2PO4+Na2HPO4 
10.2 NH3+NH4Cl 
12.0 NaOH + KCl 
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Table 2 - Sensitivities, intercepts, limits of detection, limits of quantification and other linear 
fit parameters calculated from danusertib calibration curves obtained by square wave 
voltammetry (SWV), Fig. 5A, and by UV-VIS spectrophotometry, Fig. 5B. 
 
method sensitivity intercept LOD LOQ R2 S.D. R.S.D. 
SWV 0.099±0.002 nA/nM 
-3.789±0.646 
nA 
27.4 
nM 
91.2 
nM 0.997 
0.903 
nA 5.4 % 
UV-VIS 0.024±0.001 a.u./µM 
0.001±0.002 
a.u. 
0.5  
µM 
1.6  
µM 0.996 
0.004 
a.u. 0.5 % 
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Schemes and Figures 
 
Scheme 1 – Chemical structure of: A) danusertib and B) imatinib mesylate. 
 
Scheme 2 – Proposed oxidation mechanisms of danusertib at different electroactive groups: 
A) amide at peak 1a, B) pyrrolo-pyrazol at peak 2a and C) piperazine at peak 3a.  
 
 
Fig. 1 – Cyclic voltammograms in 50 µM danusertib in pH: A) 3.4, recorded between +0.00 
V and: +1.50 V (black) first and (dotted black) second scans, (red) +0.96 V, and (grey) +1.15 
V, and B) 5.7, (black) first and (dotted black) second scans; v = 100 mV s-1.  
 
Fig. 2 – A) 3-D plot of DP voltammograms base-line corrected in 5 µM danusertib function 
of pH of the supporting electrolyte. B) Plot of Epa of peak () 1a, (z) 2a and (Ì) 3a vs. pH. 
 
Fig. 3 – DP voltammograms base-line corrected in solutions of danusertib: A) 1 µM in pH = 
4.5 (black) first and (dotted black) second scans in solution, and (red) first and (dotted red) 
second scans after transferring the electrode to the supporting electrolyte, and B) 0.1 µM in 
pH = 5.7 (black) first and (dotted black) second scans in solution. 
 
Fig. 4 – SW voltammograms base-line corrected in 5 µM danusertib in pH: A) 2.0 and B) 
12.0; It, If and Ib – total, forward and backward currents, f = 25 Hz, ΔEs = 2 mV for v = 50 mV 
s-1. 
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Fig. 5 - A) SW voltammograms in 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45 and 0.50 
µM and B) UV spectra in 1, 2, 3,4, 5, 6, 7, 8, 9, 10 µM danusertib in pH = 7.0; s.e. represents 
the voltammogram recorded in buffer; the absorbance and the peak current increase with 
solution concentration, respectively. For SW voltammetry: f = 10 Hz, ΔEs = 2 mV for v = 20 
mV s-1.  
 
Fig. 6 - DP voltammograms base-line corrected in 5 µM: A) danusertib (black) first and 
(dotted) second scans, and B) imatinib mesylate (black) first and (dotted) second scans and 
(red) piperazine citrate, in pH = 4.5. 
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Scheme 1 – Chemical structure of: A) danusertib and B) imatinib mesylate. 
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Scheme 2 – Proposed oxidation mechanisms of danusertib at different electroactive groups: 
A) amide at peak 1a, B) pyrrolo-pyrazol at peak 2a and C) piperazine at peak 3a.  
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Fig. 1 – Cyclic voltammograms in 50 µM danusertib in pH: A) 3.4, recorded between +0.00 
V and: +1.50 V (black) first and (dotted black) second scans, (red) +0.96 V, and (grey) +1.15 
V, and B) 5.7, (black) first and (dotted black) second scans; v = 100 mV s-1. 
Page 26 of 33
Ac
ce
pte
d M
an
us
cri
pt
27 
 
 
 
Fig. 2 – A) 3-D plot of DP voltammograms base-line corrected in 5 µM danusertib function 
of pH of the supporting electrolyte. B) Plot of Epa of peak () 1a, (z) 2a and (Ì) 3a vs. pH. 
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Fig. 3 – DP voltammograms base-line corrected in solutions of danusertib: A) 1 µM in pH = 
4.5 (black) first and (dotted black) second scans in solution, and (red) first and (dotted red) 
second scans after transferring the electrode to the supporting electrolyte, and B) 0.1 µM in 
pH = 5.7 (black) first and (dotted black) second scans in solution. 
Page 28 of 33
Ac
ce
pte
d M
an
us
cri
pt
29 
 
 
 
Fig. 4 – SW voltammograms base-line corrected in 5 µM danusertib in pH:  
A) 2.0 and B) 12.0; It, If and Ib – total, forward and backward currents,  
f = 25 Hz, ΔEs = 2 mV for v = 50 mV s-1. 
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Fig. 5 - A) SW voltammograms in 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45 and 0.50 
µM and B) UV spectra in 1, 2, 3,4, 5, 6, 7, 8, 9, 10 µM danusertib in pH = 7.0;  
s.e. represents the voltammogram recorded in buffer;  
the absorbance and the peak current increase with solution concentration, respectively.  
For SW voltammetry: f = 10 Hz, ΔEs = 2 mV for v = 20 mV s-1. 
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Fig. 6 - DP voltammograms base-line corrected in 5 µM: A) danusertib (black) first and 
(dotted) second scans, and B) imatinib mesylate (black) first and (dotted) second scans and 
(red) piperazine citrate, in pH = 4.5.  
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GRAPHICAL ABSTRACT 
Electrochemical and spectrophotometric characterisation of protein kinase inhibitor 
and anticancer drug danusertib 
Oana M. Popa and Victor C. Diculescu 
 
 
 
Chemical structure of danusertib and DP voltammograms recorded in  
5 µM danusertib in pH = 4.5: (black curve) first and (dotted curve) second scans. 
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HIGHLIGHTS 
 
clarify the redox mechanism of danusertib; 
pH dependent process investigated at a glassy carbon electrode;  
number of electrons and protons determined;  
analytical determination of danusertib by voltammetry and spectrophotometry; 
different electroactive centres identified and redox mechanism proposed.  
 
